Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2 (MATADOR2)
This is an interventional, prospective, single-center study designed to collect and describe genetic, environmental and psychosocial control data from male participants. The participants did not have any prior history of cancer at the time of the oncogenetic consultation and do not have the family mutation researched during the oncogenetic consultation (targeted genetic testing). The participants are referenced in the IUCT-O medical records as family members of patients suffering from male breast cancer.
The study will be conducted on a population of 120 participants.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前：Ayman AL SAATI, PharmD, PhD
- 電話番号：0033 5 31 15 52 42
- メール：alsaati.ayman@iuct-oncopole.fr
研究場所
-
-
-
Toulouse、フランス、31059
- Institut Universitaire du Cancer Toulouse - Oncopole, Laboratoire d'oncogénétique
-
コンタクト：
- Ayman AL SAATI, PharmD, PhD
- 電話番号：0033 5 31 15 52 20
- メール：alsaati.ayman@iuct-oncopole.fr
-
-
参加基準
適格基準
就学可能な年齢
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- 1. A male volunteer participant with no personal history of cancer, registered in the IUCT-O oncogenetics database as a relative of a patient carrying a pathogenic or likely pathogenic variant in one of the cancer predisposition genes routinely analyzed at the oncogenetics laboratory
- 2. Age ≥ 66 years
- 3. Participant with no known family relationship to a patient of the MATADOR1 cohort
- 4. Participant who has undergone an oncogenetic consultation at the IUCT-O
- 5. Participant who does not carry the familial mutation in any of the cancer predisposition genes previously tested
- 6. Participant for which an archived blood sample is available for the research in the oncogenetics laboratory
- 7. Participant having signed an informed consent form before inclusion in the study and before any study specific procedure
Exclusion Criteria:
- 1. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：他の
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の：Control group
The participants enrolled in this study (MATADOR2) will serve as control group for the patients enrolled in the previous study (MATADOR = MATADOR1) in order to identify:
|
In order to meet the study's objective, after written informed consent was obtained, participants will be asked to complete a questionnaire characterizing their environmental and psychosocial context. The questionnaire is to be filled out by the participants at home. It is estimated that the questionnaire will take around 30 minutes to complete. Demographics data will also be collected from the medical records of included participants.
In order to meet the study's objective, after completion of the questionnaire, a genetic analysis (Whole Exome Sequencing) will be conducted on an archived blood sample collected during the initial oncogenetics consultation.
The patient had given consent to this sample in order for the oncogenetics laboratory to perform the targeted genetic analysis (presence of family mutation).
No additional blood sample will be collected for the purpose of this study.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The environmental and psychosocial data in the questionnaire will be described by the usual descriptive statistics.
時間枠：30 days approximately for each participant, 1 year and 1 month in total for all patients
|
A 75-question questionnaire (created for the purposes of the MATADOR project) will cover such aspects as the participant's living conditions, professional situation, qualifications or level of education, social environment, early life and family environment, general health and recent significant events.
For each question of the questionnaire: quantitative variables will be described by the median, minimum, maximum and number of missing data, and qualitative variables by the numbers, percentages and number of missing data.
|
30 days approximately for each participant, 1 year and 1 month in total for all patients
|
その他の成果指標
結果測定 |
時間枠 |
|---|---|
|
The list of genetic variants of the participants will be otained through a WES (Whole Exome Sequencing) analysis
時間枠：Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。